We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-14.95%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.72B
AUM Growth
-$950M
Cap. Flow
-$368M
Cap. Flow %
-21.39%
Top 10 Hldgs %
48.56%
Holding
373
New
67
Increased
88
Reduced
111
Closed
78

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$59.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.9M
3
AMGN icon
Amgen
AMGN
+$18M
4
LLY icon
Eli Lilly
LLY
+$15.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.23M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$6.04M
2
ABT icon
Abbott
ABT
+$4.77M
3
RGNX icon
Regenxbio
RGNX
+$4.1M
4
CELG
Celgene Corp
CELG
+$3.94M
5
UTHR icon
United Therapeutics
UTHR
+$3.59M

Sector Composition

Rank Sector Weight
1 Healthcare 17.88%
2 Financials 0.23%
3 Consumer Staples 0.05%
4 Technology 0.03%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THC icon
326
CALL
Tenet Healthcare
THC
$22.6B
– –
-3,179
Closed -$7.2M
THC icon
327
Tenet Healthcare
THC
$22.6B
– –
-112,831
Closed -$2.56M
THC icon
328
PUT
Tenet Healthcare
THC
$22.6B
– –
-1,744
Closed -$3.95M
TNXP icon
329
Tonix Pharmaceuticals
TNXP
$158M
– –
0
– -$142K
UTHR icon
330
United Therapeutics
UTHR
$26.1B
– –
-28,112
Closed -$3.59M
ITCI
331
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-14,800
Closed -$209K
ITCI
332
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-148
Closed -$226K
LUMO
333
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-11
Closed -$150K
ARAV
334
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-29,161
Closed -$2.14M
INFI
335
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-167
Closed -$26K
SRNE
336
CALL
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-164
Closed -$127K
SRNE
337
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-20,986
Closed -$162K
AERI
338
CALL
DELISTED
Aerie Pharmaceuticals
AERI
– –
-1,180
Closed -$4.45M
GBT
339
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-721
Closed -$1.66M
ATHX
340
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
– –
-19
Closed -$101K
RDUS
341
CALL
DELISTED
Radius Health, Inc.
RDUS
– –
-195
Closed -$1.05M
GPL
342
DELISTED
Great Panther Mining Limited
GPL
– –
-4,045
Closed -$56.1K
CALA
343
DELISTED
Calithera Biosciences, Inc
CALA
– –
-16,225
Closed -$1.05M
ADMS
344
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-28,200
Closed -$463K
MNTA
345
CALL
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-275
Closed -$321K
DERM
346
CALL
DELISTED
Dermira, Inc.
DERM
– –
-722
Closed -$2.44M
DERM
347
PUT
DELISTED
Dermira, Inc.
DERM
– –
-678
Closed -$2.29M
GNMX
348
CALL
DELISTED
Aevi Genomic Medicine Inc
GNMX
– –
-533
Closed -$297K
ACHN
349
PUT
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-1,681
Closed -$1.36M
TSRO
350
DELISTED
TESARO, Inc.
TSRO
– –
-27,500
Closed -$3.47M
11 12 13
14
15

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sabby Management held 373 positions worth $1.72B, down 36% from $2.67B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sabby Management withdrew a net $368M in Q4 2016, closing 78 positions and reducing 111 holdings. Its most notable exit was Shire pic, an estimated $6.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 9.2% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Eli Lilly worth $15.7M.

  • Sabby Management's largest Q4 2016 buy was Eli Lilly: 213,113 shares worth $15.7M.
  • Sabby Management added most to Sarepta Therapeutics in Q4 2016, an estimated $59.4M increase.
  • Sabby Management's biggest Q4 2016 reduction was Regenxbio, cutting an estimated $4.1M.
  • Sabby Management fully exited Shire pic in Q4 2016, selling an estimated $6.04M.
  • Sabby Management's ten largest holdings make up 49% of its $1.72B portfolio in Q4 2016.
  • Sabby Management opened 67 new positions and closed 78 in Q4 2016.
  • Sabby Management's portfolio value fell 36% quarter-over-quarter to $1.72B.

Based on Sabby Management's 13F filing for Q4 2016, filed 14 Feb 2017.